BR112022024226A2 - Métodos para tratar ou prevenir uma infecção súbita por coronavírus da síndrome respiratória aguda, para tratar uma síndrome do desconforto respiratório agudo e para tratar uma disfunção imunológica ou condição hiperinflamatória em um sujeito mamífero, composição ou kit antiviral para uso em seres humanos, e, composição farmacêutica ou kit para uso na prevenção ou tratamento da síndrome respiratória aguda em um sujeito mamífero - Google Patents
Métodos para tratar ou prevenir uma infecção súbita por coronavírus da síndrome respiratória aguda, para tratar uma síndrome do desconforto respiratório agudo e para tratar uma disfunção imunológica ou condição hiperinflamatória em um sujeito mamífero, composição ou kit antiviral para uso em seres humanos, e, composição farmacêutica ou kit para uso na prevenção ou tratamento da síndrome respiratória aguda em um sujeito mamíferoInfo
- Publication number
- BR112022024226A2 BR112022024226A2 BR112022024226A BR112022024226A BR112022024226A2 BR 112022024226 A2 BR112022024226 A2 BR 112022024226A2 BR 112022024226 A BR112022024226 A BR 112022024226A BR 112022024226 A BR112022024226 A BR 112022024226A BR 112022024226 A2 BR112022024226 A2 BR 112022024226A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- acute respiratory
- kit
- syndrome
- mammal subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063031551P | 2020-05-28 | 2020-05-28 | |
| PCT/US2021/034494 WO2021243007A2 (en) | 2020-05-28 | 2021-05-27 | Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024226A2 true BR112022024226A2 (pt) | 2023-01-31 |
Family
ID=78722786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024226A BR112022024226A2 (pt) | 2020-05-28 | 2021-05-27 | Métodos para tratar ou prevenir uma infecção súbita por coronavírus da síndrome respiratória aguda, para tratar uma síndrome do desconforto respiratório agudo e para tratar uma disfunção imunológica ou condição hiperinflamatória em um sujeito mamífero, composição ou kit antiviral para uso em seres humanos, e, composição farmacêutica ou kit para uso na prevenção ou tratamento da síndrome respiratória aguda em um sujeito mamífero |
Country Status (12)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113444177A (zh) * | 2020-03-27 | 2021-09-28 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| WO2021207497A1 (en) * | 2020-04-08 | 2021-10-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Covid-19 inflammatory cytokine storm treatment |
| US20230071393A1 (en) * | 2020-04-16 | 2023-03-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome |
| US11402391B2 (en) | 2020-12-21 | 2022-08-02 | Incelldx, Inc. | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist |
| CN115252760B (zh) * | 2022-03-30 | 2024-05-31 | 厦门大学 | 一种广谱抗冠状病毒的制剂及其制备方法 |
| WO2025029797A1 (en) * | 2023-08-01 | 2025-02-06 | Incelldx, Inc. | Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19 |
| CN117304031A (zh) * | 2023-09-05 | 2023-12-29 | 深圳大学 | 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用 |
| CN117414438B (zh) * | 2023-11-01 | 2025-10-17 | 大连医科大学附属第一医院 | 一种靶向m1型巨噬细胞的多肽偶联药物及其应用 |
| CN117919385B (zh) * | 2024-02-05 | 2024-10-18 | 中国医学科学院医学实验动物研究所 | IL-37在MERS-CoV感染疾病的治疗中的应用 |
| CN121490288A (zh) * | 2025-11-21 | 2026-02-10 | 中山大学附属第三医院 | 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP223198A0 (en) * | 1998-03-06 | 1998-04-02 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| US20030109486A1 (en) * | 2001-10-31 | 2003-06-12 | Eliezer Rapaport | Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) |
| ES2464459T3 (es) * | 2008-06-25 | 2014-06-02 | H. Lundbeck A/S | Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor |
| WO2010036945A2 (en) * | 2008-09-26 | 2010-04-01 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| KR101374760B1 (ko) * | 2011-10-26 | 2014-03-17 | 한국생명공학연구원 | 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물 |
| JP6977206B2 (ja) * | 2016-03-31 | 2021-12-08 | 富山県 | 自然免疫を活性化する粘膜ワクチン用アジュバント |
| WO2019108456A1 (en) * | 2017-12-01 | 2019-06-06 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
-
2021
- 2021-05-27 CN CN202180059368.3A patent/CN117015375A/zh active Pending
- 2021-05-27 WO PCT/US2021/034494 patent/WO2021243007A2/en not_active Ceased
- 2021-05-27 AU AU2021281257A patent/AU2021281257A1/en not_active Abandoned
- 2021-05-27 CA CA3180577A patent/CA3180577A1/en active Pending
- 2021-05-27 JP JP2022573211A patent/JP2023528804A/ja active Pending
- 2021-05-27 EP EP21812442.8A patent/EP4304570A4/en active Pending
- 2021-05-27 BR BR112022024226A patent/BR112022024226A2/pt not_active Application Discontinuation
- 2021-05-27 US US17/928,235 patent/US20230248684A1/en not_active Abandoned
- 2021-05-27 KR KR1020227045667A patent/KR20230058014A/ko active Pending
- 2021-05-27 MX MX2022014958A patent/MX2022014958A/es unknown
- 2021-05-27 IL IL298593A patent/IL298593B1/en unknown
-
2022
- 2022-11-28 CL CL2022003348A patent/CL2022003348A1/es unknown
-
2023
- 2023-11-10 US US18/388,597 patent/US20240082202A1/en not_active Abandoned
-
2025
- 2025-10-17 US US19/362,286 patent/US20260041660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003348A1 (es) | 2023-12-01 |
| JP2023528804A (ja) | 2023-07-06 |
| CA3180577A1 (en) | 2021-12-02 |
| MX2022014958A (es) | 2023-04-13 |
| EP4304570A2 (en) | 2024-01-17 |
| AU2021281257A1 (en) | 2023-02-02 |
| CN117015375A (zh) | 2023-11-07 |
| US20240082202A1 (en) | 2024-03-14 |
| WO2021243007A2 (en) | 2021-12-02 |
| WO2021243007A3 (en) | 2021-12-30 |
| US20260041660A1 (en) | 2026-02-12 |
| IL298593A (en) | 2023-01-01 |
| EP4304570A4 (en) | 2025-01-22 |
| KR20230058014A (ko) | 2023-05-02 |
| US20230248684A1 (en) | 2023-08-10 |
| IL298593B1 (en) | 2026-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001337A (es) | Uso de cannabidiol en el tratamiento del sindrome de dravet. | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| BRPI0912411A8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. | |
| BRPI0514536A (pt) | uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório | |
| MX2020005719A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| MX2022014958A (es) | Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados. | |
| AR058133A1 (es) | Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea | |
| CO2023000130A2 (es) | Composición y método para el tratamiento del dolor crónico | |
| ES2074698T3 (es) | Composicion oral para el tratamiento de enfermedades intestinales inflamatorias. | |
| BR112018013227A2 (pt) | ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição? | |
| Hamdy et al. | Management of aphthous ulceration with topical quercetin: a randomized clinical trial | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| Nicolazzo et al. | Blockade of microglial Kv1. 3 potassium channels by the peptide HsTX1 [R14A] attenuates lipopolysaccharide-mediated neuroinflammation | |
| BR112018017233A2 (pt) | uso de i. butyriciproducens e/ou e. hallii, e, composição | |
| ZA202213765B (en) | Procyanidins for the treatment of endothelial dysfunction triggered by covid-19 | |
| Ebrahimi et al. | Post marketing surveillance on safety and effectiveness of ANGIPARS in treatment of diabetic foot ulcers | |
| NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
| MX2021010219A (es) | Composicion para uso en la prevencion y/o tratamiento de la disbiosis. | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| BR0107960A (pt) | Tratamento de condições alérgicas e inflamatórias | |
| BR112021018222A2 (pt) | Composição | |
| MX2022014197A (es) | Usos y formulaciones de cannabinoides. | |
| BR112022021646A2 (pt) | Usos e formulações de canabinoides | |
| CY1113544T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |